NSB clears FDA hurdle for StemSmart Crohn’s trial

FDA supports StemSmart Phase 2 pathway

NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has cleared an important regulatory checkpoint for its StemSmart™ cell therapy, with the US Food and Drug Administration supporting six of seven key elements of the company’s proposed Phase 2 trial in refractory Crohn’s disease. The feedback included agreement that no additional non-clinical studies were needed, based on the existing human treatment data, and that the proposed release-testing strategy was acceptable for the trial.

The FDA’s remaining issue concerns the manufacturing testing strategy for StemSmart™, which NSB says is being implemented with minimal impact to timelines. The company’s FDA Phase 2 design feedback was announced on 13 October, after the quarter ended, and the trial remains targeted to begin in Australia and the United States by the end of calendar 2026. That target is still contingent on completing the relevant preparation and manufacturing work.

Southern Star appointed to run clinical trial

NSB appointed Southern Star Research on 1 October to conduct the planned Phase 2 study across Australia and the US. The appointment gives the program an operational partner as the company finalises the trial protocols and prepares for initiation.

The company is also developing an open-label early-phase program for fistulising Crohn’s disease, although its design and delivery model remain unsettled. NSB says the study could proceed independently or with leading investigators and research institutions. Earlier Special Access Scheme treatment produced clinical responses in patients, but those outcomes are not a substitute for the controlled evidence the Phase 2 program is intended to generate.

Q-Gen transfer keeps manufacturing on the critical path

Technology transfer to Australia-based Q-Gen Cell Therapeutics has moved into validation, including GMP engineering and demonstration runs for StemSmart™ and qualification of testing and control processes. Data from that work is due to be assessed during a TGA inspection scheduled for October, with Q-Gen’s licence expansion required to manufacture and supply the product for NSB’s Phase 2 trials.

The manufacturing program builds on the Q-Gen technology transfer, which had previously entered development to support the planned late-2026 trials. Completion remains scheduled for the second half of calendar 2026, but the filing explicitly makes that timing subject to successful validation and the TGA audit.

Cash runway extends beyond five quarters at current burn

NSB held $3.911 million in cash and cash equivalents at 30 September, after using $719,000 in operating cash during the quarter. Research and development accounted for $409,000 of the outflow, including $49,000 tied to the Q-Gen transfer, while administration and corporate costs totalled $242,000. The company reported no financing inflow during the quarter.

On the ASX’s standard cash-flow calculation, that balance equates to 5.44 quarters of funding at the current operating rate. It is a mechanical estimate rather than a trial budget: the filing does not present the future cost of the Phase 2 program, so the runway could change as clinical activity increases. Shareholders have also approved the switch to Miro Sciences Ltd, with the proposed ASX ticker MSX taking effect on 28 October.